{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:49:23Z","timestamp":1792162163274,"version":"4.4.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12830-7","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:21:15Z","timestamp":1792160475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Hannah Lalengzuali","family":"Fanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basuvan","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalirajan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7464","authenticated-orcid":false,"given":"Gowramma","family":"Byran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"12830_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010","journal-title":"Breast"},{"issue":"22","key":"12830_CR2","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1111\/jcmm.16946","volume":"25","author":"Y Li","year":"2021","unstructured":"Li Y, Kong X, Xuan L, Wang Z, Huang Y (2021) Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment. J Cell Mol Med 25(22):10327\u201310348. https:\/\/doi.org\/10.1111\/jcmm.16946","journal-title":"J Cell Mol Med"},{"issue":"1","key":"12830_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/14756366.2022.2052868","volume":"37","author":"M Kciuk","year":"2022","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Marciniak B, Drozda R, Kontek R (2022) Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzyme Inhib Med Chem 37(1):1278\u20131298. https:\/\/doi.org\/10.1080\/14756366.2022.2052868","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"11","key":"12830_CR4","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","volume":"69","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, Sheng C, Ding K, Rao Y (2024) Targeting the undruggables\u2014The power of protein degraders. Sci Bull 69(11):1776\u20131797. https:\/\/doi.org\/10.1016\/j.scib.2024.03.056","journal-title":"Sci Bull"},{"issue":"1","key":"12830_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu T, Li X, Zhang N, Foster LJ, Peng C, Huang W, He G (2023) Recent advances in targeting the undruggable proteins: From drug discovery to clinical trials. Signal Transduct Target Therapy 8(1):335. https:\/\/doi.org\/10.1038\/s41392-023-01589-z","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"12830_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.tibs.2024.06.006","volume":"49","author":"L M\u00fcller","year":"2024","unstructured":"M\u00fcller L, Hoppe T (2024) UPS-dependent strategies of protein quality control degradation. Trends Biochem Sci 49(10):859\u2013874. https:\/\/doi.org\/10.1016\/j.tibs.2024.06.006","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"12830_CR7","doi-asserted-by":"publisher","first-page":"e202400656","DOI":"10.1002\/cbic.202400656","volume":"26","author":"A Rodr\u00edguez-Gimeno","year":"2025","unstructured":"Rodr\u00edguez-Gimeno A, Galdeano C (2025) Drug Discovery Approaches to Target E3 Ligases. ChemBioChem 26(1):e202400656. https:\/\/doi.org\/10.1002\/cbic.202400656","journal-title":"ChemBioChem"},{"issue":"1","key":"12830_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X (2024) Targeted protein degradation: Advances in drug discovery and clinical practice. Signal Transduct Target Therapy 9(1):308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x","journal-title":"Signal Transduct Target Therapy"},{"issue":"25","key":"12830_CR9","doi-asserted-by":"publisher","first-page":"e202319456","DOI":"10.1002\/anie.202319456","volume":"63","author":"CJ Diehl","year":"2024","unstructured":"Diehl CJ, Salerno A, Ciulli A (2024) Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo\u2010PROTACs. Angew Chem Int Ed 63(25):e202319456. https:\/\/doi.org\/10.1002\/anie.202319456","journal-title":"Angew Chem Int Ed"},{"issue":"5","key":"12830_CR10","doi-asserted-by":"publisher","first-page":"109574","DOI":"10.1016\/j.isci.2024.109574","volume":"27","author":"V Haridas","year":"2024","unstructured":"Haridas V, Dutta S, Munjal A, Singh S (2024) Inhibitors to degraders: Changing paradigm in drug discovery. iScience 27(5):109574. https:\/\/doi.org\/10.1016\/j.isci.2024.109574","journal-title":"iScience"},{"issue":"23","key":"12830_CR11","doi-asserted-by":"publisher","first-page":"e202400267","DOI":"10.1002\/cmdc.202400267","volume":"19","author":"Y Jin","year":"2024","unstructured":"Jin Y, Lee Y (2024) Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy. ChemMedChem 19(23):e202400267. https:\/\/doi.org\/10.1002\/cmdc.202400267","journal-title":"ChemMedChem"},{"issue":"1","key":"12830_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1021\/acsptsci.4c00408","volume":"8","author":"J Sedlacek","year":"2025","unstructured":"Sedlacek J (2025) Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs. ACS Pharmacology Translational Science 8(1):21\u201335. https:\/\/doi.org\/10.1021\/acsptsci.4c00408","journal-title":"ACS Pharmacology Translational Science"},{"issue":"8","key":"12830_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/17568919.2025.2479418","volume":"17","author":"I Shagufta, Ahmad","year":"2025","unstructured":"Shagufta, Ahmad I, Nasar NA, Zerin S (2025) Designing molecular hybrids as novel breast cancer therapeutics. Future Med Chem 17(8):857\u2013859. https:\/\/doi.org\/10.1080\/17568919.2025.2479418","journal-title":"Future Med Chem"},{"issue":"37","key":"12830_CR14","doi-asserted-by":"publisher","first-page":"e202308049","DOI":"10.1002\/anie.202308049","volume":"62","author":"N Zhang","year":"2023","unstructured":"Zhang N, Hou D, Hu X, Liang J, Wang M, Song Z, Yi L, Wang Z, An H, Xu W, Wang H (2023) Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy. Angew Chem Int Ed 62(37):e202308049. https:\/\/doi.org\/10.1002\/anie.202308049","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"12830_CR15","doi-asserted-by":"publisher","first-page":"104311","DOI":"10.1016\/j.drudis.2025.104311","volume":"30","author":"RTU Haid","year":"2025","unstructured":"Haid RTU, Reichel A (2025) PK\/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows. Drug Discovery Today 30(3):104311. https:\/\/doi.org\/10.1016\/j.drudis.2025.104311","journal-title":"Drug Discovery Today"},{"issue":"5","key":"12830_CR16","doi-asserted-by":"publisher","first-page":"e202414146","DOI":"10.1002\/anie.202414146","volume":"64","author":"Y Moon","year":"2025","unstructured":"Moon Y, Cho H, Kim J, Song S, Yeon Park J, Young Min J, Hee Han E, Kim Y, Seong J, Kyu Shim M, Kim K (2025) Self-Assembled Peptide\u2010Derived Proteolysis\u2010Targeting Chimera (PROTAC) Nanoparticles for Tumor\u2010Targeted and Durable PD\u2010L1 Degradation in Cancer Immunotherapy. Angew Chem Int Ed 64(5):e202414146. https:\/\/doi.org\/10.1002\/anie.202414146","journal-title":"Angew Chem Int Ed"},{"issue":"13","key":"12830_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","volume":"29","author":"SD Edmondson","year":"2019","unstructured":"Edmondson SD, Yang B, Fallan C (2019) Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges. Bioorganic Medicinal Chem Letters 29(13):1555\u20131564. https:\/\/doi.org\/10.1016\/j.bmcl.2019.04.030","journal-title":"Bioorganic Medicinal Chem Letters"},{"issue":"19","key":"12830_CR18","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1039\/D2CS00387B","volume":"51","author":"CJ Diehl","year":"2022","unstructured":"Diehl CJ, Ciulli A (2022) Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chem Soc Rev 51(19):8216\u20138257. https:\/\/doi.org\/10.1039\/D2CS00387B","journal-title":"Chem Soc Rev"},{"issue":"3","key":"12830_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1039\/D1CB00011J","volume":"2","author":"MJ Bond","year":"2021","unstructured":"Bond MJ, Crews CM (2021) Proteolysis targeting chimeras (PROTACs) come of age: Entering the third decade of targeted protein degradation. RSC Chem Biology 2(3):725\u2013742. https:\/\/doi.org\/10.1039\/D1CB00011J","journal-title":"RSC Chem Biology"},{"issue":"8","key":"12830_CR20","doi-asserted-by":"publisher","first-page":"eaay5064","DOI":"10.1126\/sciadv.aay5064","volume":"6","author":"M Reynders","year":"2020","unstructured":"Reynders M, Matsuura BS, B\u00e9routi M, Simoneschi D, Marzio A, Pagano M, Trauner D (2020) PHOTACs enable optical control of protein degradation. Sci Adv 6(8):eaay5064. https:\/\/doi.org\/10.1126\/sciadv.aay5064","journal-title":"Sci Adv"},{"issue":"11","key":"12830_CR21","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41418-025-01528-1","volume":"32","author":"R Gong","year":"2025","unstructured":"Gong R, Wan X, Jiang S, Guan Y, Li Y, Jiang T, Chen Z, Zhong C, He L, Xiang Z, Yang J, Xu B, Yang J, Cheng Y (2025) GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62. Cell Death Differentiation 32(11):2022\u20132037. https:\/\/doi.org\/10.1038\/s41418-025-01528-1","journal-title":"Cell Death Differentiation"},{"issue":"46","key":"12830_CR22","doi-asserted-by":"publisher","first-page":"21096","DOI":"10.1021\/jacs.2c07217","volume":"144","author":"SM Meyer","year":"2022","unstructured":"Meyer SM, Tanaka T, Zanon PRA, Baisden JT, Abegg D, Yang X, Akahori Y, Alshakarchi Z, Cameron MD, Adibekian A, Disney MD (2022) DNA-Encoded Library Screening To Inform Design of a Ribonuclease Targeting Chimera (RiboTAC). J Am Chem Soc 144(46):21096\u201321102. https:\/\/doi.org\/10.1021\/jacs.2c07217","journal-title":"J Am Chem Soc"},{"issue":"7","key":"12830_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14656566.2025.2488456","volume":"26","author":"T Mukohara","year":"2025","unstructured":"Mukohara T (2025) Vepdegestrant for the treatment of HR+\/HER2\u2013 breast cancer. Expert Opin Pharmacother 26(7):791\u2013799. https:\/\/doi.org\/10.1080\/14656566.2025.2488456","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"12830_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","volume":"41","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tang S-C (2022) The race to develop oral SERDs and other novel estrogen receptor inhibitors: Recent clinical trial results and impact on treatment options. Cancer Metastasis Rev 41(4):975\u2013990. https:\/\/doi.org\/10.1007\/s10555-022-10066-y","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"12830_CR25","doi-asserted-by":"publisher","first-page":"bqab153","DOI":"10.1210\/endocr\/bqab153","volume":"162","author":"A Mazumder","year":"2021","unstructured":"Mazumder A, Shiao S, Haricharan S (2021) HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer. Endocrinology 162(10):bqab153. https:\/\/doi.org\/10.1210\/endocr\/bqab153","journal-title":"Endocrinology"},{"issue":"1","key":"12830_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12958-024-01338-z","volume":"23","author":"TP Srivastava","year":"2025","unstructured":"Srivastava TP, Dhar R, Karmakar S (2025) Looking beyond the ER, PR, and HER2: What\u2019s new in the ARsenal for combating breast cancer? Reproductive Biology Endocrinol 23(1):9. https:\/\/doi.org\/10.1186\/s12958-024-01338-z","journal-title":"Reproductive Biology Endocrinol"},{"issue":"2","key":"12830_CR27","doi-asserted-by":"publisher","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","volume":"23","author":"Z Hu","year":"2022","unstructured":"Hu Z, Crews CM (2022) Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. ChemBioChem 23(2):e202100270. https:\/\/doi.org\/10.1002\/cbic.202100270","journal-title":"ChemBioChem"},{"key":"12830_CR28","doi-asserted-by":"publisher","first-page":"104485","DOI":"10.1016\/j.breast.2025.104485","volume":"82","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM (2025) Expert consensus on treating HR+\/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast 82:104485. https:\/\/doi.org\/10.1016\/j.breast.2025.104485","journal-title":"Breast"},{"issue":"14","key":"12830_CR29","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","volume":"68","author":"Z Ma","year":"2025","unstructured":"Ma Z, Zhou J (2025) NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders. J Med Chem 68(14):14129\u201314136. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01818","journal-title":"J Med Chem"},{"key":"12830_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/BCTT.S270799","volume":"12","author":"A Luque-Bolivar","year":"2020","unstructured":"Luque-Bolivar A, P\u00e9rez-Mora E, Villegas VE, Rond\u00f3n-Lagos M (2020) Resistance and Overcoming Resistance in Breast Cancer. Breast Cancer: Targets Therapy 12:211\u2013229. https:\/\/doi.org\/10.2147\/BCTT.S270799","journal-title":"Breast Cancer: Targets Therapy"},{"issue":"1","key":"12830_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41698-025-00931-8","volume":"9","author":"HE Marei","year":"2025","unstructured":"Marei HE, Bedair K, Hasan A, Al-Mansoori L, Gaiba A, Morrione A, Cenciarelli C, Giordano A (2025) Targeting CDKs in cancer therapy: Advances in PROTACs and molecular glues. Npj Precision Oncol 9(1):204. https:\/\/doi.org\/10.1038\/s41698-025-00931-8","journal-title":"Npj Precision Oncol"},{"issue":"23","key":"12830_CR32","doi-asserted-by":"publisher","first-page":"21186","DOI":"10.1021\/acs.jmedchem.4c01976","volume":"67","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zheng L, Ma L, Yin F, Luo Z, Li S, Jiang Y, Kong L, Wang X (2024) Discovery of Dual CDK6\/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer. J Med Chem 67(23):21186\u201321207. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01976","journal-title":"J Med Chem"},{"key":"12830_CR33","doi-asserted-by":"publisher","first-page":"1012552","DOI":"10.3389\/fphar.2022.1012552","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Yang H, Yu X, Qin J-J (2022) Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. Front Pharmacol 13:1012552. https:\/\/doi.org\/10.3389\/fphar.2022.1012552","journal-title":"Front Pharmacol"},{"issue":"10","key":"12830_CR34","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","volume":"45","author":"M Xu","year":"2024","unstructured":"Xu M, Gu X, Li C, Pan L, Zhu Z, Fan M, Zhao Y, Chen J, Liu X, Zhang X (2024) A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. Acta Pharmacol Sin 45(10):2174\u20132185. https:\/\/doi.org\/10.1038\/s41401-024-01312-w","journal-title":"Acta Pharmacol Sin"},{"key":"12830_CR35","doi-asserted-by":"publisher","first-page":"1193222","DOI":"10.3389\/fimmu.2023.1193222","volume":"14","author":"Y-Y Shi","year":"2023","unstructured":"Shi Y-Y, Wang A-J, Liu X-L, Dai M-Y, Cai H-B (2023) Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells. Front Immunol 14:1193222. https:\/\/doi.org\/10.3389\/fimmu.2023.1193222","journal-title":"Front Immunol"},{"key":"12830_CR36","doi-asserted-by":"publisher","first-page":"1520734","DOI":"10.3389\/fddsv.2025.1520734","volume":"5","author":"M Ambrose","year":"2025","unstructured":"Ambrose M, Lee J, Syed A, Ahmed Z, Peng G (2025) Non-enzymatic protein targeting agents as a promising strategy for cancer treatment. Front Drug Discovery 5:1520734. https:\/\/doi.org\/10.3389\/fddsv.2025.1520734","journal-title":"Front Drug Discovery"},{"issue":"1","key":"12830_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel R, Klein P, Tiersten A, Sparano JA (2023) An emerging generation of endocrine therapies in breast cancer: A clinical perspective. Npj Breast Cancer 9(1):20. https:\/\/doi.org\/10.1038\/s41523-023-00523-4","journal-title":"Npj Breast Cancer"},{"issue":"S1","key":"12830_CR38","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","volume":"90","author":"JFR Robertson","year":"2004","unstructured":"Robertson JFR, Harrison M (2004) Fulvestrant: Pharmacokinetics and pharmacology. Br J Cancer 90(S1):S7\u2013S10. https:\/\/doi.org\/10.1038\/sj.bjc.6601630","journal-title":"Br J Cancer"},{"key":"12830_CR39","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2147\/OTT.S236532","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Ma H, Yao J (2020) ER\u03b1, A Key Target for Cancer Therapy: A Review. OncoTargets Therapy 13:2183\u20132191. https:\/\/doi.org\/10.2147\/OTT.S236532","journal-title":"OncoTargets Therapy"},{"issue":"16","key":"12830_CR40","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Taylor IC (2024) Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res 30(16):3549\u20133563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465","journal-title":"Clin Cancer Res"},{"issue":"4","key":"12830_CR41","doi-asserted-by":"publisher","first-page":"e60889","DOI":"10.1371\/journal.pone.0060889","volume":"8","author":"W-L Yeh","year":"2013","unstructured":"Yeh W-L, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T (2013) Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor \u03b1 Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase. PLoS ONE 8(4):e60889. https:\/\/doi.org\/10.1371\/journal.pone.0060889","journal-title":"PLoS ONE"},{"issue":"6","key":"12830_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/1078-0432.CCR-21-2652","volume":"28","author":"J\u00c1 Garc\u00eda-S\u00e1enz","year":"2022","unstructured":"Garc\u00eda-S\u00e1enz J\u00c1, Mart\u00ednez-J\u00e1\u00f1ez N, Cubedo R, Jerez Y, Lahuerta A, Gonz\u00e1lez-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Ant\u00f3n A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D (2022) Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor\u2013Positive\/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clin Cancer Res 28(6):1107\u20131116. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2652","journal-title":"Clin Cancer Res"},{"key":"12830_CR43","doi-asserted-by":"publisher","first-page":"ix124","DOI":"10.1016\/S0923-7534(20)32903-3","volume":"23","author":"RS De Jong","year":"2012","unstructured":"De Jong RS, Sonke GS, Maass N, Mansouri K, Cirri L, Shi P, Hamid O, Mariani G (2012) Fulvestrant (FUL) Plus Enzastaurin (ENZA) vs FUL Plus Placebo (PBO) in Aromatase Inhibitor (AI)-Resistant Metastatic Breast Cancer (MBC): A Randomized, Double-Blind, Phase 2 Trial. Ann Oncol 23:ix124. https:\/\/doi.org\/10.1016\/S0923-7534(20)32903-3","journal-title":"Ann Oncol"},{"issue":"1","key":"12830_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40265-017-0855-5","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED (2018) Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy. Drugs 78(1):131\u2013137. https:\/\/doi.org\/10.1007\/s40265-017-0855-5","journal-title":"Drugs"},{"issue":"7","key":"12830_CR45","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s12094-017-1797-9","volume":"20","author":"I Blancas","year":"2018","unstructured":"Blancas I, Fontanillas M, Conde V, Lao J, Mart\u00ednez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, Garc\u00eda-Palomo A, Mendiola C, P\u00e9rez-Ruiz E, Bofill JS, Baena-Ca\u00f1ada JM, J\u00e1\u00f1ez NM, Esquerdo G, Ruiz-Borrego M (2018) Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol 20(7):862\u2013869. https:\/\/doi.org\/10.1007\/s12094-017-1797-9","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"12830_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamaoncol.2023.6038","volume":"10","author":"CX Ma","year":"2024","unstructured":"Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Carey LA (2024) Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor\u2013Rich\/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol 10(3):362. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6038","journal-title":"JAMA Oncol"},{"issue":"1","key":"12830_CR47","doi-asserted-by":"publisher","first-page":"101493","DOI":"10.1016\/j.esmoop.2023.101493","volume":"8","author":"PA Fasching","year":"2023","unstructured":"Fasching PA, Clifton K, Katashvili Z, Nemsadze G, Makharadze T, Arkania E, Gogishvili M, Lachowicz M, Gedrich R, Ranciato J, Zhi E, Perkins J, Ja\u00f1ez NM, Hurvitz SA (2023) 154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+\/human epidermal growth factor receptor 2 (HER2)- localized breast cancer. ESMO Open 8(1):101493. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101493","journal-title":"ESMO Open"},{"issue":"32","key":"12830_CR48","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M (2024) VERITAC-2: A Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer. Future Oncol 20(32):2447\u20132455. https:\/\/doi.org\/10.1080\/14796694.2024.2377530","journal-title":"Future Oncol"},{"issue":"1","key":"12830_CR49","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.esmoop.2023.101394","volume":"8","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Schott A, Ma CX, Nanda R, Zahrah G, Hunter N, Tan A, Telli ML, Anampa J, Jeselsohn R, Munster P, Zhi E, Gedrich R, Mather C, Han H, Hamilton E (2023) 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+\/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open 8(1):101394. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101394","journal-title":"ESMO Open"},{"key":"12830_CR50","doi-asserted-by":"publisher","first-page":"707317","DOI":"10.3389\/fchem.2021.707317","volume":"9","author":"A Bricelj","year":"2021","unstructured":"Bricelj A, Steinebach C, Kuchta R, G\u00fctschow M, Sosi\u010d I (2021) E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front Chem 9:707317. https:\/\/doi.org\/10.3389\/fchem.2021.707317","journal-title":"Front Chem"},{"issue":"3","key":"12830_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acschembio.9b00092","volume":"14","author":"MJ Roy","year":"2019","unstructured":"Roy MJ, Winkler S, Hughes SJ, Whitworth C, Galant M, Farnaby W, Rumpel K, Ciulli A (2019) SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. ACS Chem Biol 14(3):361\u2013368. https:\/\/doi.org\/10.1021\/acschembio.9b00092","journal-title":"ACS Chem Biol"},{"key":"12830_CR52","doi-asserted-by":"publisher","first-page":"112993","DOI":"10.1016\/j.ejmech.2020.112993","volume":"210","author":"P Mart\u00edn-Acosta","year":"2021","unstructured":"Mart\u00edn-Acosta P, Xiao X (2021) PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 210:112993. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112993","journal-title":"Eur J Med Chem"},{"issue":"10","key":"12830_CR53","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","volume":"60","author":"D Zaidman","year":"2020","unstructured":"Zaidman D, Prilusky J, London N (2020) PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes. J Chem Inf Model 60(10):4894\u20134903. https:\/\/doi.org\/10.1021\/acs.jcim.0c00589","journal-title":"J Chem Inf Model"},{"issue":"1","key":"12830_CR54","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz RP, Rui H, Dellamaggiore K, Ghimire-Rijal S, Choi K, Smither K, Amegadzie A, Chen N, Li X, Banerjee A, Chen Q, Mohl D, Vaish A (2023) Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun 14(1):4177. https:\/\/doi.org\/10.1038\/s41467-023-39904-5","journal-title":"Nat Commun"},{"key":"12830_CR55","doi-asserted-by":"publisher","unstructured":"Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, Zhu H, Farley KA, Ding W, Schiemer J, Feng X, Chang JS, Uccello DP, Young JA, Garcia-Irrizary CN, Czabaniuk L, Schuff B, Oliver R, Montgomery J, Calabrese MF (2018) Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci 115(31). https:\/\/doi.org\/10.1073\/pnas.1803662115","DOI":"10.1073\/pnas.1803662115"},{"issue":"19","key":"12830_CR56","doi-asserted-by":"publisher","first-page":"13029","DOI":"10.1021\/acs.jmedchem.2c00877","volume":"65","author":"V Poongavanam","year":"2022","unstructured":"Poongavanam V, Atilaw Y, Siegel S, Giese A, Lehmann L, Meibom D, Erdelyi M, Kihlberg J (2022) Linker-Dependent Folding Rationalizes PROTAC Cell Permeability. J Med Chem 65(19):13029\u201313040. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00877","journal-title":"J Med Chem"},{"issue":"20","key":"12830_CR57","doi-asserted-by":"publisher","first-page":"18124","DOI":"10.1021\/acs.jmedchem.4c01251","volume":"67","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Arashida N, Fujii T, Shikida N, Ito K, Shimbo K, Seki T, Iwai Y, Hirama R, Hatada N, Nakayama A, Okuzumi T, Matsuda Y (2024) Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody\u2013Drug Conjugates. J Med Chem 67(20):18124\u201318138. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01251","journal-title":"J Med Chem"},{"issue":"1","key":"12830_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","volume":"2","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhao J, Chen D, Wang Y (2021) E3 ubiquitin ligases: Styles, structures and functions. Mol Biomed 2(1):23. https:\/\/doi.org\/10.1186\/s43556-021-00043-2","journal-title":"Mol Biomed"},{"key":"12830_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM (2019) PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future. Drug Discovery Today: Technol 31:15\u201327. https:\/\/doi.org\/10.1016\/j.ddtec.2019.01.002","journal-title":"Drug Discovery Today: Technol"},{"issue":"16","key":"12830_CR60","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.1021\/acs.jmedchem.8b00842","volume":"61","author":"X Lucas","year":"2018","unstructured":"Lucas X, Van Molle I, Ciulli A (2018) Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel\u2013Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem 61(16):7387\u20137393. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00842","journal-title":"J Med Chem"},{"issue":"5","key":"12830_CR61","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","volume":"17","author":"JA Gramespacher","year":"2022","unstructured":"Gramespacher JA, Cotton AD, Burroughs PWW, Seiple IB, Wells JA (2022) Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins. ACS Chem Biol 17(5):1259\u20131268. https:\/\/doi.org\/10.1021\/acschembio.2c00185","journal-title":"ACS Chem Biol"},{"issue":"1","key":"12830_CR62","doi-asserted-by":"publisher","first-page":"103387","DOI":"10.1016\/j.drudis.2022.103387","volume":"28","author":"AL Saraswat","year":"2023","unstructured":"Saraswat AL, Vartak R, Hegazy R, Patel A, Patel K (2023) Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). Drug Discovery Today 28(1):103387. https:\/\/doi.org\/10.1016\/j.drudis.2022.103387","journal-title":"Drug Discovery Today"},{"issue":"12","key":"12830_CR63","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","volume":"66","author":"KR Hornberger","year":"2023","unstructured":"Hornberger KR, Araujo EMV (2023) Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders. J Med Chem 66(12):8281\u20138287. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00740","journal-title":"J Med Chem"},{"issue":"31","key":"12830_CR64","doi-asserted-by":"publisher","first-page":"e202507702","DOI":"10.1002\/ange.202507702","volume":"137","author":"X Zhang","year":"2025","unstructured":"Zhang X, Song Z, Zhang X, Zou J, Yu G, Chen X, Wang S (2025) Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy. Angew Chem 137(31):e202507702. https:\/\/doi.org\/10.1002\/ange.202507702","journal-title":"Angew Chem"},{"key":"12830_CR65","doi-asserted-by":"publisher","first-page":"RP101127","DOI":"10.7554\/eLife.101127","volume":"13","author":"KY Wu","year":"2025","unstructured":"Wu KY, Hung TI, Chang CA (2025) PROTAC-induced protein structural dynamics in targeted protein degradation. eLife 13:RP101127. https:\/\/doi.org\/10.7554\/eLife.101127","journal-title":"eLife"},{"issue":"1","key":"12830_CR66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12967-025-07610-z","volume":"24","author":"T Yue","year":"2025","unstructured":"Yue T, He J, Hou J (2025) Targeted protein degradation: Species, diseases and efficient utilization. J Translational Med 24(1):115. https:\/\/doi.org\/10.1186\/s12967-025-07610-z","journal-title":"J Translational Med"},{"issue":"3","key":"12830_CR67","doi-asserted-by":"publisher","first-page":"111248","DOI":"10.1016\/j.jbc.2026.111248","volume":"302","author":"AG Caldwell","year":"2026","unstructured":"Caldwell AG, Parmar H, Zhang X (2026) Emerging biologic modalities for targeted protein degradation. J Biol Chem 302(3):111248. https:\/\/doi.org\/10.1016\/j.jbc.2026.111248","journal-title":"J Biol Chem"},{"issue":"8","key":"12830_CR68","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1039\/D5CC05651A","volume":"62","author":"J Sheng","year":"2026","unstructured":"Sheng J, Ma T, Wu Y, Wang M (2026) Programmable PROTAC delivery for precise and spatiotemporal protein degradation. Chem Commun 62(8):2414\u20132427. https:\/\/doi.org\/10.1039\/D5CC05651A","journal-title":"Chem Commun"},{"issue":"13","key":"12830_CR69","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen C, Yang Y, Wang Z, Li H, Dong C, Zhang X (2023) Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity. J Med Chem 66(13):8428\u20138440. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00302","journal-title":"J Med Chem"},{"issue":"8","key":"12830_CR70","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","volume":"69","author":"W Peng","year":"2026","unstructured":"Peng W, Pan X, Wang S, Huang G, Qian Y (2026) New PROTAC Designs for Targeted Protein Degradation in 2021\u20132025: Novel E3 Ligases and Pre-PROTACs. J Med Chem 69(8):8688\u20138718. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03330","journal-title":"J Med Chem"},{"issue":"41","key":"12830_CR71","doi-asserted-by":"publisher","first-page":"13206","DOI":"10.1039\/D5TB01162K","volume":"13","author":"H Cho","year":"2025","unstructured":"Cho H, Kim J, Lee H, Kang H, Kim K (2025) Nanotechnology-based strategies for overcoming clinical limitations of PROTACs in cancer therapy. J Mater Chem B 13(41):13206\u201313220. https:\/\/doi.org\/10.1039\/D5TB01162K","journal-title":"J Mater Chem B"},{"key":"12830_CR72","doi-asserted-by":"publisher","unstructured":"Zhao J, Liao B, Gong Y, Li Y (2026) A Global Bibliometric and Visualized Analysis of Proteolysis Targeting Chimeras from 2015 to 20. Curr Med Chem 33. https:\/\/doi.org\/10.2174\/0109298673414312251202045402","DOI":"10.2174\/0109298673414312251202045402"},{"issue":"17","key":"12830_CR73","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1039\/D5CC05563F","volume":"62","author":"Y Hong","year":"2026","unstructured":"Hong Y, Liu X, Li Y, Yu M, Wang C, Nie C, Xu S (2026) Targeted degradation of BRD4 by PROTACs: Advances in cancer therapy. Chem Commun 62(17):4869\u20134888. https:\/\/doi.org\/10.1039\/D5CC05563F","journal-title":"Chem Commun"},{"key":"12830_CR74","doi-asserted-by":"publisher","first-page":"110446","DOI":"10.1016\/j.cellsig.2022.110446","volume":"99","author":"H Graham","year":"2022","unstructured":"Graham H (2022) The mechanism of action and clinical value of PROTACs: A graphical review. Cell Signal 99:110446. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110446","journal-title":"Cell Signal"},{"issue":"8","key":"12830_CR75","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/dmd.121.000784","volume":"50","author":"RS Jones","year":"2022","unstructured":"Jones RS, Leung C, Chang JH, Brown S, Liu N, Yan Z, Kenny JR, Broccatelli F (2022) Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs. Drug Metab Dispos 50(8):1053\u20131063. https:\/\/doi.org\/10.1124\/dmd.121.000784","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"12830_CR76","doi-asserted-by":"publisher","first-page":"e13734","DOI":"10.1111\/apha.13734","volume":"233","author":"P Indorf","year":"2021","unstructured":"Indorf P, Patzak A, Lichtenberger F (2021) Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy. Acta Physiol 233(4):e13734. https:\/\/doi.org\/10.1111\/apha.13734","journal-title":"Acta Physiol"},{"issue":"10","key":"12830_CR77","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cells14100732","volume":"14","author":"S Shah","year":"2025","unstructured":"Shah S, D\u2019Souza GGM (2025) Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis. Cells 14(10):732. https:\/\/doi.org\/10.3390\/cells14100732","journal-title":"Cells"},{"issue":"5","key":"12830_CR78","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.gendis.2025.101520","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu M, Yang X (2025) Patient-derived xenograft models: Current status, challenges, and innovations in cancer research. Genes Diseases 12(5):101520. https:\/\/doi.org\/10.1016\/j.gendis.2025.101520","journal-title":"Genes Diseases"},{"issue":"1","key":"12830_CR79","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/pharmaceutics15010195","volume":"15","author":"R Haid","year":"2023","unstructured":"Haid R, Reichel A (2023) A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs). Pharmaceutics 15(1):195. https:\/\/doi.org\/10.3390\/pharmaceutics15010195","journal-title":"Pharmaceutics"},{"issue":"22","key":"12830_CR80","doi-asserted-by":"publisher","first-page":"e202423057","DOI":"10.1002\/anie.202423057","volume":"64","author":"C Sun","year":"2025","unstructured":"Sun C, Liu S, Lau JW, Yang H, Chen Y, Xing B (2025) Enzyme-Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment\u2010Responsive Immunomodulation. Angew Chem Int Ed 64(22):e202423057. https:\/\/doi.org\/10.1002\/anie.202423057","journal-title":"Angew Chem Int Ed"},{"key":"12830_CR81","doi-asserted-by":"publisher","unstructured":"Yao H, Zhang Y, Liu M, Gao S, Yang J, Xing D, Wang C (2026) Tumor Microenvironment-Responsive PROTAC Prodrugs: A Pioneering Strategy for Precision Cancer Therapy. Adv Funct Mater e27321. https:\/\/doi.org\/10.1002\/adfm.202527321","DOI":"10.1002\/adfm.202527321"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12830-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:21:16Z","timestamp":1792160476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12830-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12830"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12830-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that there is no conflict of interest related to the manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":4,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1733"}}